226 related articles for article (PubMed ID: 28939749)
1. CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
Avril T; Etcheverry A; Pineau R; Obacz J; Jegou G; Jouan F; Le Reste PJ; Hatami M; Colen RR; Carlson BL; Decker PA; Sarkaria JN; Vauléon E; Chiforeanu DC; Clavreul A; Mosser J; Chevet E; Quillien V
Clin Cancer Res; 2017 Dec; 23(23):7360-7374. PubMed ID: 28939749
[No Abstract] [Full Text] [Related]
2. USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.
Zhou Y; Meng X; He W; Li X; Zhao R; Dong C; Yuan D; Yang J; Zhang R; Shi G; Huang Y; Liu J; Liu J; Liu S; Fu P; Sun M
Neuro Oncol; 2022 Sep; 24(9):1482-1493. PubMed ID: 35287174
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
5. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
7. Src family kinases differentially influence glioma growth and motility.
Lewis-Tuffin LJ; Feathers R; Hari P; Durand N; Li Z; Rodriguez FJ; Bakken K; Carlson B; Schroeder M; Sarkaria JN; Anastasiadis PZ
Mol Oncol; 2015 Nov; 9(9):1783-98. PubMed ID: 26105207
[TBL] [Abstract][Full Text] [Related]
8. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
9. Phostine PST3.1a Targets MGAT5 and Inhibits Glioblastoma-Initiating Cell Invasiveness and Proliferation.
Hassani Z; Saleh A; Turpault S; Khiati S; Morelle W; Vignon J; Hugnot JP; Uro-Coste E; Legrand P; Delaforge M; Loiseau S; Clarion L; Lecouvey M; Volle JN; Virieux D; Pirat JL; Duffau H; Bakalara N
Mol Cancer Res; 2017 Oct; 15(10):1376-1387. PubMed ID: 28634226
[TBL] [Abstract][Full Text] [Related]
10. EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
Wang SD; Rath P; Lal B; Richard JP; Li Y; Goodwin CR; Laterra J; Xia S
Oncogene; 2012 Dec; 31(50):5132-43. PubMed ID: 22310282
[TBL] [Abstract][Full Text] [Related]
11. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization.
Hayashi K; Michiue H; Yamada H; Takata K; Nakayama H; Wei FY; Fujimura A; Tazawa H; Asai A; Ogo N; Miyachi H; Nishiki T; Tomizawa K; Takei K; Matsui H
Sci Rep; 2016 Mar; 6():23372. PubMed ID: 26988603
[TBL] [Abstract][Full Text] [Related]
12. Biomimetic models to examine microenvironmental regulation of glioblastoma stem cells.
Nakod PS; Kim Y; Rao SS
Cancer Lett; 2018 Aug; 429():41-53. PubMed ID: 29746930
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
[TBL] [Abstract][Full Text] [Related]
14. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Atkins RJ; Stylli SS; Kurganovs N; Mangiola S; Nowell CJ; Ware TM; Corcoran NM; Brown DV; Kaye AH; Morokoff A; Luwor RB; Hovens CM; Mantamadiotis T
Exp Cell Res; 2019 Jan; 374(2):353-364. PubMed ID: 30562483
[TBL] [Abstract][Full Text] [Related]
15. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
[TBL] [Abstract][Full Text] [Related]
16. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells.
Spina R; Voss DM; Asnaghi L; Sloan A; Bar EE
Oncotarget; 2016 Jan; 7(1):459-72. PubMed ID: 26575950
[TBL] [Abstract][Full Text] [Related]
17. Coculture with astrocytes reduces the radiosensitivity of glioblastoma stem-like cells and identifies additional targets for radiosensitization.
Rath BH; Wahba A; Camphausen K; Tofilon PJ
Cancer Med; 2015 Nov; 4(11):1705-16. PubMed ID: 26518290
[TBL] [Abstract][Full Text] [Related]
18. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data.
Cheng HW; Liang YH; Kuo YL; Chuu CP; Lin CY; Lee MH; Wu AT; Yeh CT; Chen EI; Whang-Peng J; Su CL; Huang CY
Cell Death Dis; 2015 May; 6(5):e1753. PubMed ID: 25950483
[TBL] [Abstract][Full Text] [Related]
19. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin.
Kegelman TP; Wu B; Das SK; Talukdar S; Beckta JM; Hu B; Emdad L; Valerie K; Sarkar D; Furnari FB; Cavenee WK; Wei J; Purves A; De SK; Pellecchia M; Fisher PB
Proc Natl Acad Sci U S A; 2017 Jan; 114(2):370-375. PubMed ID: 28011764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
